European Journal of Biomedical and Pharmaceutical Sciences

A REVIEW ON DRUG DISCOVERY AND DEVELOPMENT FOR THE TREATMENT OF POLYCYSTIC OVARIAN SYNDROME

Kanchan M. Dodani and Mushtaque A. S. Shaikh*

ABSTRACT

Polycystic Ovarian Syndrome (PCOS), an endocrine disorder with the association of hyperandrogenism and anovulation, is the most common reproductive disorder in women. The condition further generates a constellation of different metabolic abnormalities worsening the situation more. The current treatment strategy for PCOS is rather symptomatic including drug therapy like anti-diabetic, anti-hirsutism, ovulation-inducing agents and others. However, in the past few years, there had been extensive studies on finding exact pathogenesis of PCOS and developing drugs that are curative rather than just being symptomatic. A few drugs which act as GnRH antagonist are under clinical trials for PCOS treatment. Also, NK3 receptor, extrasynaptic GABAA receptors are few other novel targets that are under investigation. An overview of pathogenesis, symptoms, treatment strategy and some novel targets has been presented in this paper.

Keywords: Polycystic Ovarian Syndrome, PCOD, NK3 Receptor, Extra synaptic GABAA receptor, Anti-Mullerian Hormone, Atrial Natriuretic Peptide, Stress.